Vicore Pharma Holding AB Stock: price and insider trades · Sweden

This page follows insider dealings at Vicore Pharma Holding AB as filed with Finansinspektionen, a company from the Health Care sector based in Gothenburg Municipality, Sweden. The group dates from 2008. The last twelve months, up to 18 October 2026, brought 5 filings signed by 5 insiders.

Not one open-market sale was filed. On the buying side, 5 insiders reported 5 purchases totalling €169k. The totals exclude 1 filing filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 3 board members, 1 finance chief and 1 chief executive. The largest single trade was a purchase of €154k by Peter Guenter, published on 15 June 2026, equal to 0.055% of the market capitalisation.

With 5 filings in twelve months, the company is quieter than the median of 7 filings across the 890 companies we follow on the same exchange. The full history, which starts in 2025, counts 6 purchases against no sales.

Within a 30-day window, 3 purchases overlapped with buying by a second insider. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The most recent open-market purchase was published on 23 September 2026, 24 days ago. Typically, a trade is published a median of 1 day after it takes place. For comparison, MAR article 19 gives managers three business days to notify a trade.

In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.